Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15746137 | 0.84 | GAA (0.42) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL1030394 | 0.81 | GAA (0.44) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL9608890 | 0.79 | GAA (0.44) | GAAMAPTLMNAALDH1A1KDM4E | |
| Ammonia Solution, Strong SCHEMBL1029966 | 0.79 | GAA (0.42) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL25303381 | 0.79 | KDM4E (0.51) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL3152486 | 0.78 | GAA (0.41) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL21768349 | 0.78 | GAA (0.43) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL3152782 | 0.77 | GAA (0.41) | GAAMAPTLMNAALDH1A1KDM4E | |
| SCHEMBL1030401 | 0.76 | BRD4 (0.45) | GAAKDM4EPOLB | |
| SCHEMBL19634920 | 0.76 | P2RX7 (0.40) | GAAGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059520-B1 | 1,4,5,6,7,8-HEXAHYDRO-I,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20100029617-A1 | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029617-A1 | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029617-A1 | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101511833-A | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2059520-A1 | 1,4,5,6, 7,8-HEXAHYDRO-I^1S-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008026149-A1 | 1,4,5,6, 7,8-HEXAHYDRO-I^1S-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008026149-A1 | 1,4,5,6, 7,8-HEXAHYDRO-I^1S-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029617-A1 | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY5R | GAA 1963/4885MAPT 1891/4885LMNA 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.